GlassScriptPhysician profile
Bryan S Blase
NPI 1700204021
$1,804.05
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $121 · 2021: $49.60 · 2022: $98.17 · 2023: $288 · 2024: $202 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835 · Education: $28.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.53 |
| Education | $28.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $314.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $239.48 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.81 | 2020-2025 | Jardiance |
| Argenx US, INC. | $197.76 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Dexcom, INC. | $123.41 | 2019 | |
| Grifols USA, LLC | $109.13 | 2022-2025 | Gamunex-C |
| Corcept Therapeutics | $74.48 | 2024 | Korlym |
| Tanabe Pharma America, INC. | $44.16 | 2023-2025 | Radicava |
| Genzyme Corporation | $40.74 | 2019 | |
| Smith+Nephew, INC. | $40.14 | 2023 | Grafix Pl |
| Medtronic Minimed, INC. | $35.46 | 2019 | |
| Merz Pharmaceuticals, LLC | $30.73 | 2025 | Xeomin |
| Pfizer INC. | $28.60 | 2023 | |
| Otter Pharmaceuticals, LLC | $27.58 | 2025 | Sympazan |
| Janssen Biotech, INC. | $27.23 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $26.99 | 2024 | Voquezna |
| Csl Behring | $25.76 | 2021 | |
| Ucb, INC. | $24.41 | 2025 | Zilbrysq |
| Abbott Laboratories | $23.84 | 2021 | |
| Aquestive Therapeutics, INC. | $23.79 | 2022 | |
| Shield Therapeutics INC | $23.45 | 2023 | Accrufer |
| Recor Medical INC | $23.04 | 2025 | Paradise Ultrasound Renal Denervation System |
| Insulet Corporation | $20.52 | 2023 | Omnipod |
| Abbvie INC. | $18.99 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.92 | 2023 | Gvoke Hypopen |
| Beta Bionics, INC. | $17.87 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $13.46 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Blase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.